Introduction —
This topic includes links to society and government-sponsored guidelines from selected countries and regions around the world. We will update these links periodically; newer versions of some guidelines may be available on each society's website. Some societies may require users to log in to access their guidelines.
The recommendations in the following guidelines may vary from those that appear in UpToDate topic reviews. Readers who are looking for UpToDate topic reviews should use the UpToDate search box to find the relevant content.
Links to related guidelines are provided separately.
●(See "Society guideline links: Monoclonal gammopathy of undetermined significance".)
●(See "Society guideline links: Waldenström macroglobulinemia".)
●(See "Society guideline links: Immunoglobulin light chain (AL) amyloidosis".)
●(See "Society guideline links: Solitary plasmacytoma".)
International
●International Myeloma Working Group (IMWG): Recommendation on sequencing immunotherapy for treatment of multiple myeloma (2025)
●IMWG: Consensus guidelines and recommendations for optimal use of T-cell-engaging bispecific antibodies in multiple myeloma (2024)
●IMWG: Consensus guidelines and recommendations for the management and response assessment of chimeric antigen receptor T-cell therapy in clinical practice for relapsed and refractory multiple myeloma (2024)
●IMWG: Recommendations for the management of multiple myeloma-related renal impairment (2023)
●IMWG: Consensus guidelines and recommendations for infection prevention in multiple myeloma (2022)
●IMWG: Consensus definition according to peripheral blood plasma cell percentage on primary plasma cell leukemia (2021)
●IMWG: Recommendations for the treatment of multiple myeloma-related bone disease (2021)
●IMWG: Recommendations for the treatment of relapsed and refractory multiple myeloma (2021)
●IMWG: Report on mass spectrometry for the evaluation of monoclonal proteins in multiple myeloma and related disorders (2021)
●Society for Immunotherapy of Cancer (SITC): Consensus statement on immunotherapy for the treatment of multiple myeloma (2020)
●IMWG: A consensus statement on the role of cement augmentation with percutaneous vertebroplasty and balloon kyphoplasty for the treatment of vertebral compression fractures in multiple myeloma (2019)
●IMWG: Consensus recommendations on imaging in monoclonal plasma cell disorders (2019)
●International Lymphoma Radiation Oncology Group (ILROG): Guidelines on radiation therapy for solitary plasmacytoma and multiple myeloma (2018)
●IMWG: Recommendations for acquisition, interpretation and reporting of whole body low dose CT in patients with multiple myeloma and other plasma cell disorders (2018)
●IMWG: A consensus statement on the role of 18F-FDG PET/CT in the diagnosis and management of multiple myeloma and other plasma cell disorders (2017)
●IMWG: An overview and consensus on second primary malignancies in multiple myeloma (2017)
●IMWG: A consensus on treatment of multiple myeloma with high-risk cytogenetics (2016)
●IMWG: Consensus criteria for response and minimal residual disease assessment in multiple myeloma (2016)
●American Society of Blood and Marrow Transplantation (ASBMT), European Society of Blood and Marrow Transplantation (EBMT), Blood and Marrow Transplant Clinical Trials Network (BMTCTN), and IMWG: Guidelines on salvage hematopoietic cell transplantation in patients with relapsed multiple myeloma (2015)
●IMWG: A consensus statement on the role of magnetic resonance imaging in the management of patients with multiple myeloma (2015)
●IMWG: Consensus on risk stratification in multiple myeloma (2014)
●IMWG: Consensus statement for the management, treatment, and supportive care of patients with myeloma not eligible for standard autologous stem-cell transplantation (2014)
●IMWG: Criteria for the diagnosis of multiple myeloma, update (2014)
●IMWG: Recommendations for global myeloma care (2014)
●IMWG: Consensus statement on diagnostic requirements, response criteria, and treatment recommendations for plasma cell leukemia (2013)
●IMWG: Consensus on maintenance therapy in multiple myeloma (2012)
●IMWG: Management of treatment-emergent peripheral neuropathy in multiple myeloma (2012)
●IMWG: Consensus approach to the treatment of multiple myeloma patients who are candidates for autologous stem cell transplantation (2011)
●IMWG: Consensus statement regarding the current status of allogeneic stem-cell transplantation for multiple myeloma (2010)
●IMWG: Consensus statement and guidelines regarding the current status of stem cell collection and high-dose therapy for multiple myeloma and the role of plerixafor (AMD 3100) (2009)
●IMWG: Guidelines for serum-free light chain analysis in multiple myeloma and related disorders (2009)
●IMWG: Mobilization in myeloma revisited – Consensus perspectives on stem cell collection following initial therapy with thalidomide-, lenalidomide-, or bortezomib-containing regimens (2009)
●IMWG: Prevention of thalidomide- and lenalidomide-associated thrombosis in myeloma (2008)
Canada
●Canadian Consensus Guideline Consortium (CGC): Recommendations for first line treatment of newly diagnosed transplant eligible multiple myeloma (2025)
●Canadian Myeloma Research Group CGC: Recommendations for first line treatment of newly diagnosed transplant ineligible multiple myeloma (2023)
●Canadian Myeloma Research Group CGC: Recommendation for the management of myeloma manifestations and complications (2022)
●Canadian Physiotherapy Association (CPA): Clinical practice guidelines for mobilization and exercise intervention for patients with multiple myeloma (2021)
●Myeloma Canada Research Network (MCRN) CGC: Consensus guidelines on the diagnosis of multiple myeloma and related disorders (2020)
●American Society of Clinical Oncology (ASCO) and Cancer Care Ontario (CCO): Joint clinical practice guideline for the treatment of multiple myeloma (2019)
●CCO: Recommendation report on stem cell transplantation in multiple myeloma (2012)
United States
●American Society for Transplantation and Cellular Therapy (ASTCT): Guideline – Survey on evaluation and management of relapsed/refractory multiple myeloma after failure of chimeric antigen receptor T cell therapy (2024)
●American Society of Clinical Oncology (ASCO) and Cancer Care Ontario (CCO): Joint clinical practice guideline on the treatment of multiple myeloma (2019)
Europe
●European Myeloma Network (EMN): Review and consensus statement on primary plasma cell leukemia (2025)
●EMN: A consensus report for prevention and management of adverse events during treatment with bispecific antibodies and CAR T cells in multiple myeloma (2023)
●European Haematology Association (EHA)-European Society for Medical Oncology (ESMO): Clinical practice guidelines for diagnosis, treatment, and follow-up on multiple myeloma (2021)
●EMN: Consensus recommendations for vaccination in multiple myeloma (2021)
●EMN: A frailty position paper for defining the vulnerable patient with myeloma (2020)
●EMN: A consensus statement on chimeric antigen receptor T-cell therapy for multiple myeloma (2019)
●EMN and Italian Society of Arterial Hypertension (SIIA): A consensus paper for the prevention, monitoring, and treatment of cardiovascular adverse events in myeloma patients receiving carfilzomib (2019)
●EMN: A consensus on the prevention and management of adverse events of novel agents in multiple myeloma (2018)
●EMN: From transplant to novel cellular therapies in multiple myeloma – Guidelines and future perspectives (2018)
●EMN: Patient-centered practice in elderly myeloma patients – An overview and consensus (2018)
●EMN: Recommendations on diagnosis and management of patients with rare plasma cell dyscrasias (2018)
●EMN: Recommendations on tools for the diagnosis and monitoring of multiple myeloma – What to use and when (2018)
●EMN: Guidelines for the management of multiple myeloma-related complications (2015)
●EBMT: A position statement on autologous haematopoietic stem cell mobilisation in multiple myeloma and lymphoma patients (2014)
●EMN: Recommendations on the evaluation and treatment of newly diagnosed patients with multiple myeloma (2014)
●EMN: Optimizing the use of lenalidomide in relapsed or refractory multiple myeloma – Consensus statement (2011)
●EMN: Recommendations of an expert panel on the use of bisphosphonates in multiple myeloma (2009)
United Kingdom
●British Society for Haematology (BSH): Good practice paper for the diagnosis and management of smouldering myeloma (2024)
●BSH/UK Myeloma Forum (UKMF): Guidelines on the diagnosis, investigation and initial treatment of myeloma (2021)
●National Institute for Health and Care Excellence (NICE): Guideline on myeloma – Diagnosis and management (2016, updated 2018)
●BSH: Guidelines for the use of imaging in the management of patients with myeloma (2017)
●UKMF and BSH: Guidelines for screening and management of late and long-term consequences of myeloma and its treatment (2017)
●UKMF: Position statement on the use of bendamustine in myeloma (2014)
●UKMF: Position statement on the use of consolidation and maintenance treatment in myeloma (2014)
India
●Indian Council of Medical Research (ICMR): Consensus document for management of multiple myeloma (2017)
Australia–New Zealand
●New Zealand Myeloma Interest Group (NZMIG): Consensus statement on the treatment of transplant-eligible patients with newly diagnosed multiple myeloma in New Zealand (2023)
●Medical Scientific Advisory Group to Myeloma Australia (MSAG MA): Bortezomib, lenalidomide, and dexamethasone (VRd) for initial treatment of multiple myeloma, update (2020)
●MSAG MA: Clinical practice guideline on multiple myeloma, update (2019)
●Royal Australasian College of Physicians (RACP): Position paper on bisphosphonate guidelines for treatment and prevention of myeloma bone disease (2017)
●MSAG MA: Position statement on the treatment of patients with multiple myeloma who are eligible for stem cell transplantation (2015)
